Friday, July 25, 2014

Why does marijuana cause paranoia?

[The title was written by my editor. It is misleading because the research did not thoroughly answer that question.]

Several psychological factors that contribute to the onset of short-term paranoia in marijuana users were identified in a new study.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


The largest study of its kind now shows that the psychoactive ingredient in cannabis is associated with short-term paranoia in users. Scientists also determined those cognitive mechanisms responsible for initiating paranoia in subjects under the influence of marijuana.

Professor Daniel Freeman and colleagues at the University of Oxford identified worrying, poor self-esteem, anxiety, and unsettling changes in perceptions as most-correlated factors in prompting paranoia in human subjects injected with Δ9-tetrahydrocannabinol, or THC, the psychoactive ingredient found in marijuana.

“The study very convincingly shows that cannabis can cause short-term paranoia in some people,” said Professor Freeman in a statement. “But more importantly it shines a light on the way our mind encourages paranoia. Paranoia is likely to occur when we are worried, think negatively about ourselves, and experience unsettling changes in our perceptions.”

Paranoia is essentially unusually strong beliefs that others are conspiring to do one harm to the point of irrationality and delusion. Although cannabis has long been suspected of causing paranoia, this study marks the first conclusive link between THC and short-term paranoia in some subjects.

The researchers tested 121 subjects between the ages of 21 and 50, all of whom had a history of cannabis use but no mental illness. Roughly 67 percent of the subjects were injected with THC, while the remaining third received a placebo injection. Among the subjects that received THC, 50 percent reported having paranoid thoughts, compared with 30 percent of the placebo group. The paranoia in the THC group declined as the drug cleared from their systems.

Subjects who experienced paranoia also most commonly reported experiencing anxiety, worry, poor mood, negative thoughts of self, echoing thoughts, changes in perceptions of sound and color in the form of pronounced intensity, and disruptions in perceptions of time.

The report was published this week in the journal Schizophrenia Bulletin, an Oxford University Press publication.

California faces $6.7 billion decision regarding hepatitis C drug

Gilead Sciences, maker of the pre-exposure prophylaxis drug Truvada, is back in the news with another extraordinarily costly drug for treating hepatitis C, but can states afford to provide it for their Medicaid recipients?

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


California is looking at a potential $6.7 billion price tag for treating its Medi-Cal enrollees with hepatitis C with a relatively new drug called Sovaldi. Sovaldi, made by Gilead Sciences, costs $1,000 per person per day, and round of treatment lasts twelve weeks. This works out to be $84,000 per patient. However, Gilead Sciences argues that the cost is reasonable considering that the drug works so well. Research has shown as many as nine of ten patients with the most common form of hepatitis C are cured, and patients are literally clamoring to get it.

The crucial question facing California decision-makers is whether the state can afford it. California is not exactly thriving economically, and providing Sovaldi to all of its eligible Medi-Cal (the state’s version of Medicaid, a federal healthcare program for the poor) enrollees, which includes prisoners, will cost each resident of the state $174 next year. Other states are also facing this fiscal dilemma. In Louisiana, for example, providing the hepatitis C treatment to those on Medicaid who will likely benefit from the drug will cost each resident an estimated $294. This works out to be a substantial Medicaid tax increase for a single drug.

Other states facing enormous price tags for subsidized Sovaldi treatments include Texas, Illinois, New York, and Florida, according to estimates by an outfit called Express-Scripts Holding Company, a large pharmacy benefits manager.

“There is no doubt that Sovaldi is a breakthrough therapy, but unfortunately, it is also likely to break state budgets,” wrote Dr. Steve Miller, Express-Scripts’ chief medical officer, in an analysis of the Sovaldi issue. “Since health care for so many hepatitis C patients is funded by state programs, each citizen will be shouldering the unprecedented cost burden. The unsustainable pricing of this medication has essentially become a tax on all Americans.”

Sovaldi was approved for treatment of hepatitis C back in December 2013. In only one quarter, Gilead saw $2.3 billion in sales, making the drug a record-breaker. Second quarter sales are expected to be strong as well.

Gilead Sciences also sells Truvada, a high-cost drug recently recommended for use in HIV prevention by the U.S. Centers for Disease Control and Prevention. When contacted, Gilead declined comment.

Researchers find a mutation that prevents alcohol intoxication

Researchers altered the gene for a human brain ion channel, put it in place of a worm’s version of the channel, and observed resistance to drunkenness among the worms.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


People fond of saying, “I’d rather have a bottle in front of me than a frontal lobotomy” may now have a glimmer of hope for one day lowering their dependence on alcohol with a new approach. While the pharmaceutical potential of a new research finding is not known, authors speculate that their work paves the way for further development.

Researchers at the University of Texas report this week in the Journal of Neuroscience that single amino acid change in an important brain protein protects against drunkenness. The scientists designed a mutated gene that encodes for the human BK channel, or “Big Potassium” channel, and placed it into a model organism called Caenorhabditis elegans. The nematode worm model is very popular among laboratory-based molecular biologists and geneticists.

Once the C. elegans worms had the mutated human BK channel instead of their own version of the crucial protein, they could tolerate alcohol exposure without showing signs of intoxication. Meanwhile, worms having only normal BK channels responded to alcohol with slower movements and inhibited egg-laying, among other intoxication indicators.

“This is the first example of altering a human alcohol target to prevent intoxication in an animal,” said corresponding author Jon Pierce-Shimomura in a statement. Pierce-Shimomura is an assistant professor in the university’s College of Natural Sciences and Waggoner Center for Alcohol and Addiction Research.

A profound aspect of this research is that the mutated BK channels function exactly like their unaltered counterparts except in their response to alcohol.

“We got pretty lucky and found a way to make the channel insensitive to alcohol without affecting its normal function,” said Pierce-Shimomura.

The BK channel is important in regulation of the activity of neurons, blood vessels, and cells in the respiratory tract and urinary bladder. None of these functions appear to be altered by the mutation engineered by Pierce-Shimomura and colleagues.

“Our findings provide exciting evidence that future pharmaceuticals might aim at this portion of the alcohol target to prevent problems in alcohol abuse disorders,” said Pierce-Shimomura. “However, it remains to be seen which aspects of these disorders would benefit.”

Concussions may affect long-term memory and cognition

A bump on the head may have longer-lasting effects on thinking and remembering than experts realized up to now, according to a new study.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Our brains may be a bit more deserving of gentle care than most assume. According to a new study, a mild to moderate concussion may have more long-term effects on cognitive function than generally thought. These new findings have implications on how safe contact athletics really are, especially for youth.

Researchers at Newcastle and Aberdeen Universities in the U.K. compared brain images and cognition test results from people with mild concussions to those from healthy people. What they found is that the recovery of cognition, or thinking activities, takes longer than long assumed.

Concussions are injuries involving bruising of the brain when the brain is bounced off of the inside of the skull’s brain case as a result of sudden impact or jarring. Some experiences that commonly cause mild concussions include falls on ice, bicycle crashes, being in a low-speed car accident, and getting punched in the face or head during a fist fight.

The new study revealed that individuals who were tested shortly after their concussive injuries scored 25 percent lower on cognition tasks compared with healthy subjects. A year later, the test results were similar but the comparisons of brain images showed that alterations were still evident, both in terms of structure and in function.

“[I]t’s really good for people to know—those who are suffering with school performance, physical performance and even social issues—the fact that there is actual structural damage, even a year after the injury,” remarked Dr. Michael O’Brien of Boston Children’s Hospital. O’Brien is director of the Hospital’s sports concussion clinic and was not involved with the study.

The report, which is published online ahead of print this week in the journal Neurology, comes precisely when debate is heating up over the concussions suffered during this year’s World Cup play.

Illinois lawmakers approve medical marijuana for qualified patients

Illinois joins the ranks of states that allow use of marijuana for medical purposes, and the new rules will allow patients that meet approval criteria to have access by the spring of 2015.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Lawmakers in the state of Illinois finalized new rules on Tuesday that will allow regulated access to medical marijuana for some patients. Patients with qualifying medical conditions and other criteria may begin applying for identification cards this fall in order to purchase cannabis for medical purposes sometime next spring.

There are many details yet to work out before medical marijuana goes on the market in Illinois, however. Regulators have yet to choose which businesses will be licensed to grow and sell marijuana. Also pending are plans to establish safety testing protocols, policies, and facilities.

Entrepreneurs who wish to open their own dispensaries and growing operations are faced with challenges specific to raising plants that have been illegal for many years. One major question to be answered is where growers may acquire seeds.

“I guess they should fall from the sky,” quipped Bryan Willmer, owner of Grand Prairie Farms in Frankfort. Willmer wishes to open cultivation centers in three counties as well as a dispensary.

The Illinois Department of Agriculture is in the process of converting an existing laboratory into a testing center where pot potency may be assessed along with screening for mold and pesticides. Meanwhile, state officials are trying to work out how seeds will be purchased.

On the near horizon—within the next 30 days—criteria will be established for scoring business applications. Up to 21 cultivation centers and 60 retail dispensaries across the state are anticipated.

The American Medical Association remains opposed to the legalization of marijuana but supports ongoing research efforts. Scientific investigations into safety and efficacy of marijuana have generally provided ambiguous results.

The U.S. Drug Enforcement Administration still classifies marijuana as a Schedule I controlled substance, a class of dangerous drugs that also includes heroin and LSD. State laws do not override federal mandates. However, in a look-the-other-way spirit of sorts, federal prosecutors have indicated that they will not prosecute patients complying with state law.

How a day at the lake can leave you with a brain-eating amoeba

The recent death of a young Kansas girl underscores the concern of brain-eating amoebae present in fresh water bodies warmed by intense summer sunlight.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Swimmers often welcome the warm temperatures of summer, particularly when the intense sunlight warms water in their favorite lakes and ponds. However, there is a rare but serious threat lurking in some of these pleasant waters. The recent death of a nine-year-old Kansas girl serves as a grim reminder.

The potentially deadly agent in some warm water bodies is an amoeba that once in the brain, destroys neurons by feeding on them. The single-celled organism Naegleria fowleri, a kind of amoeba, thrives in water that warms into the 70 to 80 degree Fahrenheit range. According to the U.S. Centers for Disease Control and Prevention (CDC), the amoeba may be present in fresh water lakes, ponds, rivers, hot springs, untreated swimming pools, and even home hot water heaters. Even tap water that has not been sufficiently treated with chlorine may potentially harbor the nasty agents.

Some experts link the risk of amoeba exposure to climate change. Dr. Clayton Wiley at the University of Pittsburgh Medical Center’s division of neuropathology hypothesizes that an overall warming of summer temperatures may translate into more bodies of water containing more of these microscopic creatures.

The risk of infection is extremely rare, but cases are nearly always lethal. Among approximately 132 suspected or documented cases since 1962, only three have survived, according to the CDC. Last year, 13-year-old Kali Hardig of Benton, Arkansas, survived an infection she contracted while swimming in a local water park. Her symptoms were fever and severe headache.

“I took her temperature and it was 103.6,” mother Traci Hardig said in a telephone interview. “I couldn’t get it to go down and it kept going up. She wouldn’t drink anything and then she started projectile vomiting. Her eyes rolled back in her head and I said, ‘Oh my God, there is something really wrong with this baby.’”

The amoeba needs to enter the body through the nasal passages so water-goers are advised to keep water out of their noses and flush their sinuses well after a suspected exposure.

Thursday, July 24, 2014

Friends tend to have similar genetic makeup, research shows

While simple observation tells us that human beings tend to socialize with similar-looking members of the race, new research digs deeper to show a startling similarity in genetic makeup among friends.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


They say that birds of a feather flock together, and human beings tend to choose friends that look like them. Now surprising new results of a genetic comparison reveals that friends share some amazing genetic similarities, raising the question of whether we choose our friendships or are they, at least in part, determined by genetics.

Researchers at Yale and the University of California, San Diego (UCSD), report this week in the Proceedings of the National Academy of Sciences that “friends may be a kind of ‘functional kin.’” In other words, we tend to befriend people who not only look similar to us but also have certain genetic similarities to us as well. These genetic similarities are complex too.

“Your friends don’t just resemble you superficially, they resemble you genetically,” said Nicholas A. Christakis, a co-author on the report. Christakis is a physician and social scientist at Yale University.

The scientists used comparisons of single-nucleotide polymorphisms (SNPs) among friends and strangers to determine to what extent and in which genetic regions or genes the similarities and differences occur. The similarities in genetic aberrations, the SNPs, were on the level of fourth cousins, the researchers note.

“We can do better than chance at predicting if two people are going to be friends if all we have is their genetic data,” said James Fowler, senior author and professor of medical genetics and political science at UCSD.

What was particularly interesting among the findings of the study is that the genetic similarities were mainly in two types of genes: olfactory, or sense of smell, and immunity. Even so, the overall genetic similarity amongst friends is only about one percent. There are no single genes that link friends, either. Still, the implications are tremendous.

“Social networks are an important engine for human evolution,” Fowler said. “Our friends are sort of like family members. They’re functional kin.”

Sharp rise in testicular cancer noticed in young Hispanic men

Testicular cancer has been on the rise in white men, but researchers noticed a sharp increase in U.S. Hispanic adolescents and young adult men since 1992.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Testicular cancer has been and remains to be a disease that occurs more in white men ages 15 to 39, but a new study reveals that the disease is occurring more often than before in a group that has historically received less attention: Hispanics.

Dr. Rebecca H. Johnson and colleagues at the University of Washington in Seattle compared testicular germ cell tumor trends among Hispanic and non-Hispanic white males from 1992 to 2010. They analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database was maintained by the National Cancer Institute for two periods, 1992 to 2010 and 2000 to 2010, sampling 15 and 28 percent of the U.S. population, respectively.

Johnson and colleagues found that while rates really did not change for white men over the study period 2000 through 2010, the incidence rate for Hispanics increased 3.8 percent per year during this decade. The rates increased for all age groups up to age 39. In contrast, white men at most ages showed no rate increase, with the exception of a small increase among white men in their 20s and early 30s.

Overall, the rate for all cancers in Hispanics did not increase over the years studied. The cause of the increase in testicular cancer rates is unknown. The study design used with SEER data cannot provide causal information. Regardless, the results suggest that if the rates of testicular cancer among Hispanics continues to increase as it has, Hispanics will overtake non-Hispanic whites in overall testicular cancer rate.

“All male adolescent and young adult patients should be made aware by their primary care provider about the risks of testicular cancer, regardless of ethnicity,” said Dr. Nicholas G. Cost to Reuters Health. Cost is a testicular cancer researcher at the University of Texas but was not involved with the study.

The study is described in a report published this week in the journal Cancer.

Wednesday, July 16, 2014

The Common and Serious Problem of Lyme Disease

Lyme disease is nothing to take lightly, as Women’s National Basketball Association (WNBA) rookie stand-out Elena Delle Donne demonstrates with a recurrence of the sometimes stubborn condition that has her sidelined indefinitely.

by John B. Tyburski, PhD, MPH
Youth Fitness Advisory Board
Copyright © 2014 Youth Fitness Council, LLC. All rights reserved.


Last week the Chicago Sky announced that guard/forward Elena Delle Donne returned to her home in Delaware to seek continued treatment for recurrent Lyme disease. The WNBA rookie of the year has already missed five games in June but scored 13 points in a recent loss to Connecticut. Now she is sidelined with no speculation as to when she may return, according to team officials.

“It’s extremely frustrating for her, obviously physically, but it takes a mental toll as well,” Sky coach Pokey Chatman told The Associated Press. “She tries to be-stoic about everything. But I told her, this thing is real and you are doing the right thing by dealing with it.”

The 6-foot-5 Delle Donne, known in the league and among her fans as “EDD,” had an exemplary college career at Delaware, despite missing play on three separate occasions because of Lyme disease. This season, she averaged 21.2 points per game with the Sky.

In North America, Lyme disease is caused by spirochete bacteria (Borrelia burgdorferi) transmitted from small mammals to humans by ticks, mainly deer ticks. The name “Lyme” was coined from two towns in Connecticut, Lyme and Old Lyme, in which a number of cases of the disease were recorded in 1975 before pathological agent and vector information were discovered. It was in 1978 that investigators determined that ticks are the vector or transmitter for the disease, but it was not until 1981 that the bacteria that cause Lyme infection were isolated by entomologist Willy Burgdorfer, the namesake of B. burgdorferi.

Ticks acquire the spirochete bacteria from biting and feeding on the blood of infected small mammals, most often the white-footed mouse. The infected ticks can then transmit the bacteria to new hosts during subsequent blood feedings. It can take less than 24 hours for a tick to infect a human or other animal host. Interestingly, deer ticks cannot acquire the bacteria from deer, even infected deer. However, deer serve as highly mobile dispersion agents for infected ticks, exhibiting a strong propensity for invading highly populated human population centers, especially under the dark cloak of night.

According to the U.S. Centers for Disease Control and Prevention, over 30,000 new cases of Lyme disease are recorded each year. It is the most commonly reported vector-borne illness in the U.S., but it does not occur uniformly through the country. Cases reported in 2012 in only thirteen states accounted for about 95 percent of all cases for that year. Lyme disease is concentrated in the northeast (Virginia, Maryland, Pennsylvania, Delaware, New Jersey, New York, Connecticut, Massachusetts, Vermont, New Hampshire, and Maine) and in the northcentral (Minnesota and Wisconsin) U.S. In 2012, it was the 7th most common Nationally Notifiable disease.

The symptoms of Lyme disease vary depending on time after infection. Within three to 30 days after an infecting tick bite, approximately 70 to 80 percent of patients will exhibit an expanding red rash called erythema migrans (EM). This is the “bull’s-eye rash” often associated with Lyme disease. This rash may or may not form around the infecting bite wound. During this period, infected individuals may also experience fatigue, headache, fever, chills, muscle and joint aches, and swollen lymph nodes. A few different antibiotics are commonly prescribed at this stage of illness.


Early disseminated stage (days to weeks post-tick bite)

Untreated, the infection may spread from the site of the bite to other parts of the body, producing an array of specific symptoms that may come and go, including:

  • Additional EM lesions in other areas of the body
  • Facial or Bell’s palsy (loss of muscle tone on one or both sides of the face)
  • Severe headaches and neck stiffness due to meningitis (inflammation of the spinal cord)
  • Pain and swelling in the large joints (such as knees)
  • Shooting pains that may interfere with sleep
  • Heart palpitations and dizziness due to changes in heartbeat

Many of these symptoms will resolve over a period of weeks to months, even without treatment. However, lack of treatment can result in additional complications lasting years.

When left untreated, the infection may spread to distant parts of the body and manifest in additional EM rashes, pain and swelling in the large joints, facial palsy, severe headaches and neck stiffness from meningitis, heart palpitations from carditis, and dizziness as a result of irregular heartbeat. This early disseminated stage is usually observed days or weeks following an infecting tick bite. Intermittent arthritis with severe joint pain and swelling, shooting pain, numbness or tingling in hands or feet, and interruptions of short-term memory may occur in late disseminated stage, which is typically months to years after the infecting tick bite.

Even with early detection and proper treatment with antibiotics, about ten to 20 percent of patients may experience what is called Post-treatment Lyme disease syndrome, or PTLDS. This chronic condition can last months to years and manifests as muscle and joint pains, cognitive defects, sleep disturbances, or fatigue. No evidence has been found for persistent presence of B. burgdorferi in these patients and some investigation suggests an autoimmunity component, but not much is really known about the cause or causes of PTLDS.


Are children at risk for Lyme disease?

Yes, of course. In fact, approximately 25 percent of all documented Lyme disease cases involve children. The CDC reports that boys of ages five to 19 years exhibit the most cases at three times the average rate for all other age and gender groups. Like with any adverse health condition, Lyme disease in children brings issues unique to these young patients.

According to the non-profit corporation LymeDisease.org, special consideration must be given to recognizing Lyme disease risk and infection in children. For one, a very important challenge regarding Lyme disease in children is achieving accurate and timely diagnosis because children have less experience and ability to communicate about what it means to feel “normal” as well as “ill.” What is more, the symptoms of early localized Lyme disease mimic and may be mistakenly attributed to other, more common illnesses. It is difficult to assess changes in these symptoms, especially worsening trends. Finally, a very long list of symptoms has been assembled from numerous pediatric case reports, indicating that properly diagnosing Lyme disease in children can be extraordinarily challenging. The reader is referred to the organization’s pediatric Lyme disease resource for details.

comprehensive guide to Lyme disease is available for download from the CDC. Families residing in the states mentioned earlier should review this and other resources periodically and be always vigilant in checking for ticks and monitoring for symptoms. The CDC also makes available a number of communication tool kits for specific groups, including parents and adult leaders and coaches. As with most diseases, early detection is a key determinant in preventing Lyme disease from becoming a chronic condition.  


Minimize the Risks

As they say, “prevention is the best medicine.” For parents and adult leaders in area with high Lyme disease incidence, preventing tick bites in children should be a top priority.
  • Learn to recognize ticks in their various life stages.
  • If possible, avoid tick-infested areas such as deep grass and dense forests where large populations of deer are observed.
  • Clothe children in light-colored clothing that makes ticks easier to spot and covers as much of the body as possible.
  • Use DEET-containing insect repellent on exposed skin and spray permethrin solution onto clothing.
  • Secure both wrist and ankle cuffs to prevent ticks from gaining access to bare skin through these openings.
  • Thoroughly inspect for ticks after being outdoors.
  • Inspect any bedding or seating areas for ticks.
  • Remove ticks immediately; they may be killed by immersing in rubbing alcohol.
In short, be informed, aware, and diligent in preventing tick bites to prevent Lyme disease. Use EDD’s hiatus from WNBA play as a wake-up call to how serious this illness can be for the active child.


Treatments

Patients treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Antibiotics commonly used for oral treatment include doxycycline, amoxicillin, or cefuroxime axetil. Patients with certain neurological or cardiac forms of illness may require intravenous treatment with drugs such as ceftriaxone or penicillin.

Approximately 10-20% of patients (particularly those who were diagnosed later), following appropriate antibiotic treatment, may have persistent or recurrent symptoms and are considered to have Post-treatment Lyme disease syndrome (PTLDS). The National Institutes of Health (NIH) has funded several studies on the treatment of Lyme disease which show that most patients recover when treated with a few weeks of antibiotics taken by mouth. For details on research into what is sometimes referred to as “chronic Lyme disease” and long-term treatment trials sponsored by NIH, visit the NIH Lyme Disease web site.

For detailed recommendations on treatment, consult the 2006 Guidelines for treatment developed by the Infectious Diseases Society of America. Additional information on prolonged treatment for Lyme disease is also available.


FDA scrambling to catch up with e-cigarette market, assess safety

Some researchers are asking volunteer “vapers” to tell them how many puffs they are taking on e-cigarettes while others will search Facebook posts for any information they can find on how users are modifying their devices to deliver more nicotine.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Groups of researchers are receiving funding to determine how much people are using electronic or e-cigarettes, how they are altering their devices, and how effective online marketing is at getting children to buy the e-cigarettes and the vapors used in them.

The new research is part of a total of 48 funded projects totaling $270 million the U.S. Food and Drug Administration (FDA) is putting toward urgent investigations into the possible risks associated with e-cigarettes. The most important problem the FDA is facing in assessing e-cigarette risks is how fast the market for e-cigarettes has grown in recent years and how fast it is growing now.

“They want data and they want it yesterday,” said Dr Suchitra Krishnan-Sarin of Yale University to Reuters. Krishnan-Sarin is leading four FDA-funded e-cigarette projects.

Most biomedical research projects funded by federal agencies last five years, and this puts completion of most research aims in the e-cigarette-related projects at 2018 at the earliest. Meanwhile, makers of e-cigarettes and related products are selling in an essentially unregulated market as the pace of scientific research allows a regulatory vacuum to persist. However, the FDA will not regulate a product without evidence that regulation is necessary. While e-cigarettes deliver nicotine through the inhalation of a nicotine-laced vapor, this is where the similarity with traditional tobacco-based cigarettes ends.

“There shouldn’t be regulations akin to those for cigarettes without evidence of similar health impact, especially since the preliminary evidence is positive for the industry,” attorney Bryan Haynes told Reuters. His Richmond, Virginia-based firm, Troutman Sanders, represents e-cigarette manufacturers.

The world’s largest tobacco companies are backing most of the e-cigarette industry. The expected sales revenue around the world for 2014 with e-cigarettes is projected at $2 billion. Currently in the U.S., over 14 million adults and almost two million children under 18 have used e-cigarettes. According to the most recent data available, usage doubled among high-school-age children from 2011 to 2012.

According to one agency spokeswoman, the FDA “will always make regulatory decisions based on the best available science.”

XXX: Spiciest burger in the world?

Two journalists in the U.K. were hospitalized after trying to eat a burger alleged to be up to 16 times spicier than pepper spray.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


The British are not really known for spicy food, but at least one U.K. establishment may be serving the hottest burger on the planet. For two U.K. journalists, the burgers were spicy enough to land them in the hospital.

Ruari Barratt and Arron Hendy ordered the “XXX Hot Chili Burger,” an insanely spicy menu item at a place in Hove called Burger Off. Minutes after one bite, Barratt felt serious stomach pain and numbness in his hands. His legs began shaking, and his eyes rolled back in his head, according to a report by The Argus.

Said Barratt in a statement, “It was hard to walk. I needed to drink milk to neutralise the burning, which was hard because I was hyperventilating so much my hands had seized up.”

Hendy also took only a bite and decided the secret sauce was just too spicy. Although he did not experience an immediate reaction, he eventually suffered similar problems severe enough to join Barratt at the hospital.

“I was in so much pain I was telling people I felt like I was dying,” said Hendy. “It’s embarrassing but it felt that bad. If you’re thinking of trying this burger for a dare, just don’t.”

Burger Off owner Nick Gambardella is well-aware of the serious nature of his spicy burger. He will not serve the burger to anyone under 18 years of age or to anyone who has not signed a waiver releasing the staff from responsibility for any adverse health effects.

The sauce used in the burger is about a seven to nine million on the Scoville spiciness scale, Gambardella estimates.  Pepper spray typically measures from 500,000 to 5 million scale units, while Tobasco sauce comes in at a mere 2,500 to 5,000.

“We do try and take a certain level of responsibility,” said Gambardella. “I spend about as much time convincing people not to try one as I do selling them. I tell people it will ruin their weekend.”

Combining vaccines may help eliminate polio

For children younger than five years of age, supplementing oral vaccine with a shot of inactivated poliovirus vaccine substantially boosts intestinal immunity to the crippling poliovirus.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Polio is rarely considered among the general public in developed countries but until poliovirus is eradicated, all children, regardless of where they reside, are at risk. Recently, poliovirus exhibited resurgence in the Middle East and Africa, prompting concern among public health officials who warn of global susceptibility.

Today, oral poliovirus vaccine (OPV) is given to children at risk for poliovirus infection to prevent the disease. However, OPV is not 100 percent effective, and the immunity it confers diminishes over time. Vaccinated children may become infected with, and transmit, poliovirus.

Injecting inactivated poliovirus vaccine (IPV) in an arm by itself does not protect a child from contracting polio because the immunity must be induced in the intestinal mucosa where poliovirus attacks. This is why OPV is more effective and preferred.

According to a new report published on Jul. 11 in the journal The Lancet, however, IPV may still offer a boost in protection to children when used in combination with OPV.  Last year, Indian and British scientists conducted an open-label, randomized controlled trial in 450 children, ages one through four years from Vellore, India.

All of the children enrolled in the study had received OPV prior to enrollment. Half of the children were randomly assigned to receive IPV while the other half received nothing. A month later, all children were challenged with live OPV as a simulation of infection. Their stools were tested for poliovirus serotypes 1 and 3.

Children who received IPV and whose stools tested positive for serotypes 1 or 3 numbered 38 percent and 70 percent fewer, respectively, compared with children who did not receive IPV.

“An additional dose of the injected vaccine is more effective at boosting immunity against infection than the oral vaccine alone,” says Nick Grassly, a professor of vaccine epidemiology at Imperial and co-author on the report. “This implies that the IPV could be used to boost immunity in people travelling from or to polio-infected countries.”

Promising new drug developed for treating psoriasis

A new drug with a narrow therapeutic target has been shown in two clinical trials to rapidly and effectively treat psoriasis in some patients while causing fewer side effects than current pharmaceutical treatments.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


There is nothing flaky about these results from two large clinical trials, which show dramatic improvements seen in patients with psoriasis, who took a new drug designed to treat the chronic skin disease.

The new drug, secukinumab, was tested in two year-long phase three, double-blind, placebo-controlled clinical trials comparing its efficacy and safety to those of placebo and the best current pharmaceutical psoriasis treatment, Enbrel. The improvements for many patients were dramatic.

“Over a quarter of patients have not a dot of psoriasis left,” said study co-author Dr. Mark Lebwohl, Chairman of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City. “Over half the patients have a 90 percent improvement in their psoriasis, and that means there’s hardly any psoriasis left.”

Psoriasis is a chronic skin condition caused by overproduction of skin cells. The symptoms are patches of thick red discoloration of the skin, often with flaky white lesions. The National Psoriasis Foundation estimates that about 7.5 million Americans, or about 2.2 percent, suffer from psoriasis and often experience burning and itching as a result.

Secukinumab is an engineered antibody against an inflammatory signaling protein that has already been implicated in psoriasis called interleukin-17A. While current treatments target the whole immune system, this new drug only targets one specific protein. Therefore, with such pinpoint accuracy, this drug causes fewer side effects while targeting what is likely a primary cause or major player in psoriasis.

The improvements seen in patients taking secukinumab are the best seen from any treatment to date, according to Lebwohl.

The U.S. Food and Drug Administration is reviewing the application for using secukinumab for treating psoriasis. Novartis Pharmaceuticals, the maker of secukinumab, sponsored the research.

The report describing the two trials was published on Jul. 9 in the New England Journal of Medicine.

Obama Administration unveils drug control policy for 2014

With the use of opioid drugs on the rise and medicinal and recreational marijuana gaining momentum, the White House Office of National Drug Control Policy announces its latest update to its blueprint for reducing drug use and associated consequences.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Acting Director of the Office of National Drug Control Policy Michael Botticelli unveiled the Obama Administration’s latest update to their 2014 National Drug Control Strategy in Roanoke, Virginia, on Wednesday.

“This Strategy,.. rejects the notion that we can arrest and incarcerate our way out of the nation’s drug problem,” said Botticelli in a press conference held at a drug treatment facility in Roanoke. “Instead, it builds on decades of research demonstrating that while law enforcement should always remain a vital piece to protecting public safety, addiction is a brain disorder—one that can be prevented and treated, and from which people recover.”

Roanoke was chosen as the site for the unveiling because it is a city that has success in implementing plans on a municipal level that are similar to plans for the national level outlined in the 2014 Strategy. These include providing access to treatment with a focus on compassion and prevention, as well as the commitment to alternatives to incarceration for drug offenders. One way in which Roanoke has demonstrated its commitment to this approach is through establishing Virginia’s first ever drug court. In addition, both Roanoke’s and the White House’s plan includes the flexibility for local solutions to meet local challenges.

Botticelli acknowledged that the update involves little change to the existing policies but stressed that it does increase the focus on the growing concern surrounding heroin use and prescription painkiller abuse.

“With the reports of increasing heroin use in many American communities, including right here in Virginia, we are growing increasingly concerned by the potential transition from prescription opioid abuse to heroin and injected drug use,” Botticelli said.

Meanwhile, the White House’s opposition to the legalization of medical and recreational marijuana remains the same.

“Because quite honestly it sends the wrong message to our youth,” said Botticelli.

Sunday, July 13, 2014

Alcohol advertisements super effective on underage drinkers

Researchers find that the most favorite brands of alcohol among underage drinkers in the U.S. happen to be the same ones advertised most often in the magazines they are reading.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Never underestimate the power of advertising, especially when seen by unintended audiences. Researchers at the Johns Hopkins Bloomberg School of Public Health (JHSPH) report this week in the Journal of Studies on Alcohol and Drugs that the brands of alcohol most often advertised in magazines read by youth happen to be the same brands most often consumed illegally by youth.

“We’ve got at least 14 long-term studies that have looked at young people’s exposure to alcohol advertising and found that the more exposed they are the more likely that they are to start drinking or if already drinking, to drink more,” senior author David Jernigan told Reuters Health. “So we try to monitor youth exposure to that advertising because it’s a risk factor for underage drinking.” Jernigan is director of the JHSPH Center on Alcohol Marketing and Youth.

The alcohol industry voluntarily conforms to standards that include only placing advertisements for their products in magazines with less than 30 percent of readers under the age of 21. Youth between the ages 18 and 20 account for the highest rates of both heavy episodic, or “binge” drinking, and drinking disorders. Evidence suggests that this age group sees more alcohol brand advertisements than intended.

Jernigan and colleagues studied the advertisements in 124 national magazines during 2011 and matched their results to readership data used to identify which age groups read the magazines and the advertisements within. They found that 25 brands already known to be popular with underage drinkers were also the brands most visible in advertisements in the magazines. The researchers observed that the other, less-popular alcohol brands among youth were not as visible in advertisements.

“It’s striking that we looked at the top 25 brands among males and the top 25 among females and 308 other brands managed to reach the legal aged audience more effectively than the underage audience,” Jernigan said. “We sometimes call this advertising that flies under the parental radar.”

Study finds most successful method to quit smoking

Though the approach is more costly, smokers who wish to quit are more likely to be successful if they use both nicotine patches and the drug Chantix at the same time, according to an industry-sponsored study.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Many smokers say they would quit smoking if they could. In fact, nicotine is an enormously addictive substance, and inhaling nicotine-containing smoke delivers the most nicotine in the shortest time over any other delivery system. Of course, overwhelming evidence supports associations between smoking and adverse respiratory effects including lung cancer, emphysema, and chronic pulmonary obstructive disorder. The public health problem in smoking cessation is not in motivation but in overcoming the addiction to nicotine and smoking tobacco.

Now researchers claim that using two specific smoking cessation aids, nicotine patches and the drug Chantix (generic name varenicline), in combination improves the odds that smokers will be successful in their efforts to quit. The combination treatment costs more, of course, and there are health risks associated with Chantix, but the benefits of smoking cessation outweigh these drawbacks, said the U.S. Food and Drug Administration two years ago.

The report describing the new study appears in the July 9 issue of the Journal of the American Medical Association. The objective of the study was to assess the effectiveness and safety to using Chantix and nicotine patch compared with Chantix alone when attempting to quit smoking.

“The combination appears to be safe, although further studies are needed to confirm this,” said Dr. Coenie Koegelenberg, the report’s lead author and associate professor of pulmonology at Stellenbosch University and Tygerberg Academic Hospital, South Africa.

The 446 mostly female smokers enrolled in the study were randomly assigned to take Chantix with either nicotine or placebo patch two weeks before their target quit date. The blinded study followed the subjects for 12 weeks after the quit dates and checked on them again six months later.

At both followup assessments, more subjects who used Chantix and nicotine patch (55 and 49 percent) were still not smoking compared with the subjects who used Chantix and placebo patch (41 and 33 percent).

Friday, July 11, 2014

Brain bleed in Motörhead fan caused by overzealous headbanging

Rocking out to heavy metal can be hazardous to one’s health, as one fan of the well-known rock group Motörhead can attest after treatment for brain bleeding.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Quiet Riot advised the world in 1983 to “Bang your head—mental health will drive you mad.” They might have added that the headbanging may cause one’s brain to bleed.

Doctors in Germany reported treating a Motörhead fan for brain injury resulting from his headbanging habit but stressed that the case is unusual and that the risk of brain injury from this type of activity is low.

At the beginning of the year, a 50-year-old man was treated at Hannover Medical School after he complained of constant and worsening headaches. He had no history of head injuries or drug use. After further questioning, he revealed that he had been a long-time headbanger and had most recently did a lot of headbanging at a Motörhead concert he attended with his son.

Doctors ordered a magnetic resonance imaging (MRI) scan and upon examination of the results found that the man’s brain was bleeding. He needed to have a hole drilled through his skull through which the blood could be drained. The patient’s headaches subsided, and doctors found a benign cyst in followup scans that might have predisposed the man to his injury.

“We are not against headbanging,” said Dr. Ariyan Pirayesh Islamian, one of the doctors who treated the man. “The risk of injury is very, very low. But I think if [our patient] had [gone] to a classical concert, this would not have happened.”

Bleeding in the head causes displacement of brain tissue and an increase of intracranial pressure that can slowly choke off the vital blood supply to the brain. Left untreated, brain bleeds can be debilitating and even fatal. Brain bleeds occur when the brain bumps against the inside wall of the skull violently enough to rupture a blood vessel.

The case of the headbanging brain-bleeder is described this week in the journal The Lancet.

Sitting quietly even worse than electric shock for most men, study finds

Researchers find that most men will pay to avoid unpleasant stimuli but will still chose that unpleasant experience over sitting quietly alone with only their own thoughts.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Is sitting alone with nothing to do, nothing to fondle, and nothing to look at unpleasant for many people? This is a question that was recently answered by a group of University of Virginia researchers. The results of their investigation are…shocking.

Published in Science Magazine on July 4, the report documents 11 studies in which participants were required to sit from six to 15 minutes in isolation with no devices or distractions. They only thing they had to think about or do was entertain their own thoughts. This was more unpleasant to most than doing mundane tasks and even receiving painful stimuli.

“I’m really excited to see this paper,” said Matthew Killingsworth in a Science news article. Killingsworth is a psychologist at the University of California (UC), San Francisco, who said his own work has turned up a similar result. “When people are spending time inside their heads, they’re markedly less happy.”

University of Virginia psychologist Timothy Wilson and colleagues recruited hundreds of undergraduate students and community volunteers to participate in a series of 11 studies to determine whether people enjoyed quiet time. They found rather that most people enjoyed doing some activity such as listening to music or using a smartphone. When given the opportunity, some even chose self-administer an electric shock over sitting quietly doing nothing.

“Those of us who enjoy some down time to just think likely find the results of this study surprising – I certainly do – but our study participants consistently demonstrated that they would rather have something to do than to have nothing other than their thoughts for even a fairly brief period of time,” Wilson said in a statement.

An important finding was a gender difference; about two-thirds of the men studied administered shocks to themselves to avoid sitting quietly, compared with only 25 percent of the women studied.

New species of shrew-like Sengi discovered in Africa, more closely related to elephants

A new species of Sengi, a small, shrew-like mammal about the same size a mouse, was discovered in Africa, and genetic sequence comparisons show it is more closely related to animals much larger than itself.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Now with the latest contribution to the debate on whether size matters, followers can assuredly conclude that it does not when predicting how close two different mammalian species are genetically related.

Researchers with the California Academy of Sciences recently discovered a new species of Sengi. The name Sengi is a Bantu-language-derived common name for the Macroscelidesgenus. The newly discovered species was calledM. micus. The interesting thing about M. micusis that it has a little protruding snout not unlike the truncated elephant trunk.

The researchers noted that during the identification process that the specimens they were collecting from a remote northwestern region of Nambia were substantially different from the sengis specimens in museum collections. The scientists collected a total of 16 specimens from this region several times from 2005 to 2011.

Genetic analysis revealed that the species was, in fact, novel, as the animal’s DNA did not match that of sengi specimens already on hand. What was even more interesting though was the finding that the little furry creatures were not as closely related to other mammals of its own size and general appearance (save for the snout) as they are to elephants, sea cows, and aardvarks.

“Had our colleagues not collected those first invaluable specimens, we would never have realized that this was in fact a new species, since the differences between this and all other known species are very subtle,” said Jack Dumbacher, Academy Curator of Ornithology and Mammalogy.

The report describing the research team’s work on M. micus is published in the Journal of Mammology.

Aspiring model poses with Colostomy bag to advocate Crohn’s awareness

Bethany Townsend has the beauty to chase her dream of being a model, but another important calling prompted her to reveal the consequences of her long, difficult history of Crohn’s disease: her colostomy bag.

by John Tyburski
Copyright © Daily Digest News, KPR Media, LLC. All rights reserved.


Crohn’s disease is a form of inflammatory bowel disease (along with ulcerative colitis) that progressively destroys the large bowel. Crohn’s disease is also a risk factor for colon cancer but for young Bethany Townsend, the ravages of an almost life-long battle with Crohn’s are obvious in a powerful image she recently posted to the social media site Facebook. Townsend’s goal for the photo was to raise awareness for Crohn’s disease so that momentum may pick up for efforts in curing the chronic condition.

Townsend is picture-perfect in nearly every way except for one thing people are not used to seeing, her colostomy bag. She recently shared her story with an advocacy organization called Crohn’s and Colitis U.K.

“Finally, after three and a half years, I decided that my colostomy bags shouldn’t control my life,” Townsend wrote. “So when I went to Mexico with my husband in December last year I finally showed I wasn’t ashamed. Still hoping for a cure.”

Townsend, who resides in Worcester, England, said she has suffered from Crohn’s disease since the age of three but was 11 by the time she was properly diagnosed. By then, her condition required that a 16-inch segment of her bowel be surgically removed. Subsequently, she has endured pharmaceutical treatments including steroids, infliximab, and methotrexate plus a feeding tube for four years and a total of five surgeries.

Unfortunately, Townsend ultimately suffered a rupture of her bowel that meant from then on she would need to use a colostomy bag in place of her large intestine. A colostomy bag is a collection device worn on the outside of the body and connected to the distal end of the small intestine by way of a fistula.

Townsend is hoping for approval in the U.K. of an experimental new drug. Otherwise, her last option is a bowel transplant.

Approximately 1.4 million people in the U.S. suffer from Crohn’s disease.